Strengthening Health Products Regulatory Systems to Enhance Access to Quality Health Products in the Asia-Pacific

被引:7
作者
Lim, John C. W. [1 ]
机构
[1] Duke NUS Med Sch, Ctr Regulatory Excellence, 8 Coll Rd, Singapore 169857, Singapore
关键词
regulatory systems strengthening; regulatory convergence; regulatory excellence; Asia-Pacific; regulatory innovation;
D O I
10.1177/2168479018769285
中图分类号
R-058 [];
学科分类号
摘要
Asia-Pacific is a region of fast growing opportunity for biomedical research and marketing of new health products by pharmaceutical and medical device companies. While national regulatory authorities have the responsibility to ensure timely access to innovative, effective, and safe therapies, many face capacity and resource constraints that limit their ability to guarantee a robust regulatory system capable of licensing and monitoring novel medicines and medical devices, and tackling substandard and falsified products. The region's regulatory landscape is also fragmented with country-specific requirements that create barriers to entry for new health products. To help address these challenges, the Duke-National University of Singapore's (Duke-NUS) Centre of Regulatory Excellence (CoRE) was established in 2014 with the strategic goals to strengthen the region's regulatory agencies through capacity development, regulatory convergence, work sharing, and nurturing networks for leadership and systems innovation. A smart and mature regulatory system in Asia-Pacific is pivotal to promote biomedical innovation and enhance equitable, sustainable access of populations to quality health products that are safe and efficacious.
引用
收藏
页码:751 / 754
页数:4
相关论文
共 19 条
[1]  
[Anonymous], EMA HTA WORKSH BRING
[2]  
Asia Partnership Conference of Pharmaceutical Associations (APAC), 2014, AN REP ID CLAR DIFF
[3]  
Asian Development Bank, 2016, GREAT MEK SUBR HLTH
[4]  
Ball D., 2016, ADB BRIEFS, V54
[5]  
BMI Research, 2017, AS PHARM HEALTHC REP
[6]  
Centre of Regulatory Excellence, 2015, AS DEV BANK ADB PROJ
[7]   The role of health technology assessment bodies in shaping drug development [J].
Ciani, Oriana ;
Jommi, Claudio .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 :2273-2281
[8]  
Deloitte, 2016, GLOBAL LIFE SCI OUTL
[9]   Universal health coverage: good health, good economics [J].
Frenk, Julio ;
de Ferranti, David .
LANCET, 2012, 380 (9845) :862-864
[10]  
Gottlieb S., 2017, FDA Voice